Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meglumine cyclic adenylate
- Development stage
- Unknown
- Lead developer
- Wanbang Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Meglumine cyclic adenylate (also known as meglumine adenosine cyclophosphate or meglumine cAMP) is a small-molecule cyclic AMP (cAMP) analog and phosphodiesterase inhibitor. It is a 1:1 compound of cAMP and meglumine, which improves the water solubility and membrane permeability of cAMP. Meglumine cyclic adenylate acts as a non-glycoside positive inotropic agent and vasodilator, raising intracellular cAMP levels to enhance myocardial contractility, improve cardiac output, and reduce myocardial oxygen consumption. It is approved and widely used in China for the treatment of cardiovascular conditions, including heart failure, myocarditis, sick sinus syndrome, coronary heart disease, and cardiomyopathies. Additionally, it has been investigated preclinically for acute spinal cord injury, systemic inflammatory response syndrome, and cerebral ischemia/reperfusion injury.
- Brand names
- FuxinHuanlinkangKaiciLizhiMeilexinShengjiboShuxin'anWanfuXimaishuXin Xian AnXinxian'anYuniqing
- Other names
- MCAadenosine cyclic phosphate megluminemeglumine adenosine cyclophosphatemeglumine cAMPmeglumine cyclic adenosine monophosphatemeglumine cyclic adenylate注射用环磷腺苷葡胺环磷腺苷葡胺环磷腺苷葡胺注射液
02
Targets
ADCY3 (Adenylyl cyclase 3)PDE4D (Phosphodiesterase 4D)PKA (Cyclic amp-dependent protein kinase)
Beyond the preview
Go deeper on meglumine cyclic adenylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meglumine cyclic adenylate.